U.S. Markets open in 1 hr 26 mins

Cesca Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2018 and Host Conference Call on August 13

RANCHO CORDOVA, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the second quarter ended June 30, 2018 on Monday, August 13, 2018 after the close of trading. A conference call and webcast will follow at 4:30 p.m. EDT (1:30 p.m. PDT).

Participants may access the call by dialing 1-844-889-4331 within the U.S. or 1-412-380-7406 outside the U.S. and referencing “Cesca.” To access a live webcast of the call, please visit: https://services.choruscall.com/links/kool180813.html.

A replay of the call will be available until September 13, 2018 and can be accessed by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and referencing access code 10122202.

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (the “Company”) develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com